Please use this identifier to cite or link to this item:
|Title:||The impact of long-term testosterone replacement therapy on lipid and lipoprotein profiles in women|
|Authors:||Goh, H.H. |
Coronary vascular diseases
|Citation:||Goh, H.H., Loke, D.F.M., Ratnam, S.S. (1995). The impact of long-term testosterone replacement therapy on lipid and lipoprotein profiles in women. Maturitas 21 (1) : 65-70. ScholarBank@NUS Repository.|
|Abstract:||The lipid and lipoprotein profiles of 39 female transsexuals, exposed to testosterone esters (250 mg monthly) for an average duration of 33 months after their sex reassignment operation (group 2), were compared to those of 29 normal menstruating female transsexuals prior to starting androgen therapy (group 1). A third group, comprising 17 postoperative female transsexuals were studied while on, and after stopping their androgen therapy for 6-12 months (group 3). The average concentration of testosterone in androgenized women was comparable to those found in norma] males and levels of SHBG were significantly lower than those in the control group. No significant difference was noted between all levels of lipids and lipoproteins in pre-operative subjects of group I and corresponding levels in subjects of group 3 after they had stopped their androgen therapy for 6-12 months. Significantly higher levels of triglyceride (Trig), total cholesterol (TC), low-density lipoprotein (LDL-C) and apolipoprotein-B (Apo B) and a significantly lower level of high-density lipoprotein-cholesterol (HDL-C) were noted in androgenized women (group 2) when compared to controls (group 1?. The two atherogenic indices, LDL-C/HDL-C and Apo-AI/Apo-B were significantly raised and lowered, respectively. Similar results were noted when comparing lipid and lipoprotein profiles in subjects of group 3 while they were on and after stopping their androgen therapy. Results from this study indicate that testosterone, per se, at supraphysiological doses may promote atherogenicity in women. Furthermore, the male predilection for coronary vascular diseases (CVD) may be due to the adverse effects of higher androgen levels on lipid and lipoprotein profiles.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 11, 2018
WEB OF SCIENCETM
checked on May 16, 2018
checked on Mar 11, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.